Cookie Policy

A full description of our cookie policy can be found here.

Essential (Required)

Cookies that the site cannot function without. This includes cookies for access to secure areas and CSRF protection. Please note that Craft's default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.

Name: CraftSessionId
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionName config setting. This cookie will expire as soon as the session expires.
Provider: biocatalysts.com
Expiry: Session

Name: *_identity
Description: When you log into the control panel, you’ll get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
Provider: biocatalysts.com
Expiry: Persistent

Name: *_username
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
Provider: biocatalysts.com
Expiry: Persistent

Name: CRAFT_CSRF_TOKEN
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.
Provider: biocatalysts.com
Expiry: Session

BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year

BRAIN Biotech AG, a leading provider of integrated solutions for the biologisation of industry, today published its 9M results of FY2023/2024.

Published 30 August 2024

Home/ Media & Resources/ BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year

Cash on-hand at € 13 million
Significantly improved operating cash-flow in the 9M
Forecasting a sequentially strong BioProducts quarter in Q4 FY 23/24

BRAIN Biotech AG has built up a strong cash position of € 13.0 million within the 9M period by successfully executing several refinancing operations, primarily with debt instruments.

Turnover in the BioProducts segment, which comprises the product business with specialty enzymes and other proteins, increased slightly from € 30.3 million to € 30.4 million in the reporting period. Total operating performance amounted to € 30.1 million and was therefore 2.0% lower than in the same period of the previous year. Turnover in the third quarter amounted to € 10.5 million, representing a dynamic increase of 11.1 % compared to the same period of the previous year (€ 9.5 million). Adjusted EBITDA in the BioProducts segment fell from € 3.3 million to € 3.0 million. This is mainly due to higher personnel costs resulting from the recruitment of new production staff for future growth and operating start-up costs for the commissioning of the second large-scale fermenter.

The 9M period has seen a strong improvement of the operating cash flow from € -4.5 million in the period last year to € -2.7 million during this reporting period. This improvement was primarily driven by strong working capital control and stringent receivables management.

Read the rest of the press release here.

“

I am especially pleased by new key customers choosing BRAIN Biotech and Biocatalysts as their partner. These are further evidence that we are a proven partner in this competitive market and they will help drive our growth in the years to come. Our solid cash position forms a strong basis to keep delivering on our mid-term strategy.

— Adriaan Moelker, CEO BRAIN Biotech AG